T-cell vaccination in multiple sclerosis
T-cell vaccination in multiple sclerosis
复制标题
DOI：
10.1016/s1568-9972(03)00060-0
复制
发表时间：
2004-01-01
影响因子：
13.6
通讯作者：
Mandel, M
中科院分区：
文献类型：
--
作者：
Achiron, A;Mandel, M
对髓鞘抗原具有自身反应性的T细胞在多发性硬化（MS）的发病机制中起关键作用。T细胞疫苗接种（TCV）的概念已经发展到产生针对这些自身反应性致病性T细胞的免疫应答。迄今为止积累的免疫学数据表明，在实验性自身免疫性脑脊髓炎动物模型以及接种疫苗的MS患者中，免疫后对免疫显性髓鞘肽具有反应性的T细胞耗竭。临床试验已经证实了TCV在少数免疫MS患者中的安全性和有效性。TCV导致复发率降低，并减缓神经功能障碍和MRI脑损伤负荷的进展。最近，已经有几个双盲，安慰剂对照研究开始评估TCV在MS中的作用。具体来说，重要的是要检查早期TCV的效果，提示疾病的第一次发作后，以防止表位扩散的过程。(C)2003 Elsevier B.V.保留所有权利。
T cells that are autoreactive against myelin antigens play a pivotal role in the pathogenesis of multiple sclerosis (MS). The concept of T cell vaccination (TCV) has been developed to generate an immune response against these autoreactive pathogenic T cells. Immunologic data accumulated so far demonstrates depletion of T cells reactive against immunodominant myelin peptides after immunization in the animal model of experimental autoimmune encephalomyelitis, as well as in vaccinated MS patients. Clinical trials have confirmed the safety and efficacy of TCV in a small number of immunized MS patients. TCV resulted in reduced relapse rates and slowed the progression of neurological disability and MRI brain lesion load. Recently, there have been several double-blind, placebo-controlled studies initiated to evaluate the role of TCV in MS. Specifically, it is important to examine the effect of early TCV, given after the first episode suggestive of the disease, in order to prevent the process of epitope spreading. (C) 2003 Elsevier B.V. All rights reserved.